The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.
New York, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Intravenous (IV) Iron Drugs Industry" - https://www.reportlinker.com/p06051284/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Intravenous (IV) Iron Drugs Market to Reach $4.8 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Intravenous (IV) Iron Drugs estimated at US$2.7 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2022-2030. Ferric Carboxymaltose, one of the segments analyzed in the report, is projected to record a 7.7% CAGR and reach US$2.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Iron Dextran segment is readjusted to a revised 6.7% CAGR for the next 8-year period.
The U.S. Market is Estimated at $949.1 Million, While China is Forecast to Grow at 10.8% CAGR
The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$949.1 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$658.4 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 6.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$550.2 Million by the year 2030.
Select Competitors (Total 33 Featured)
- Allergan Plc.
- AMAG Pharmaceuticals Inc.
- American Regent Inc.
- Luitpold Pharmaceuticals
- Pharmacosmos A/S
- Sanofi US
- Vifor Fresenius Medical Care Renal Pharma
- Vifor Pharma Ltd.
Read the full report: https://www.reportlinker.com/p06051284/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Iron Deficiency Anemia (IDA) - A Major Global Health Concern
EXHIBIT 1: Iron Deficiency Prevalence by Disease: Analyzed by
Percentage Number of Patients with ID and IDA in CKD (with
dialysis), Non-Dialysis-CKD, Congestive Heart Failure,
Chemotherapy Induced Anemia, Irritable Bowel Disease,
Patient Blood Management (Surgery), Heavy Uterine Bleeding
and Postpartum (OB-GYN)
Impact of Covid-19 and Global Economic Update
War & Inflation Supersede COVID-19 as Major Downside Risks for
the Global Economy in 2023 & Beyond
Here?s How Inflationary Pressures Affect the Economy
Russia-Ukraine War, the Primary Culprit Responsible for the
Hardships
Stubbornly High Inflation to Single Handedly Drag Down Global
Growth
Here?s What?s Causing the Current Spike in Inflation
EXHIBIT 2: War-Induced Commodity Price Increases & Broad Based
Price Pressures Mark the Return of Global Inflation in 2022 to
the Highest Level Seen Since 1996: Global Inflation Rates (In
%) for the Years 2019 Through 2024
EXHIBIT 3: War, Global Inflation, Cost of Living Crisis, Failed
Fiscal Policy Attempts to Restore Price Stability & Contain
Downside Risks to Result in Sharper-Than-Expected Slowdown in
Global Economic Growth: World Economic Growth Projections:
(Real GDP, Annual % Change) for the Years 2020, 2021, 2022
and 2023
EXHIBIT 4: Recession Triggered by Uncontrolled Inflation or
Unemployment, Which is the Greater Evil? Inflation Battling
Policy Measures to Slowdown Post Pandemic Recovery in
Unemployment Rates: Global Number of Unemployed People (In
Million) for Years 2019 Through 2023
Competitive Landscape
EXHIBIT 5: Intravenous (IV) Iron Drugs - Global Key Competitors
Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
33 Players Worldwide in 2023 (E)
Global Market Overview and Prospects
Global Intravenous Iron Drugs Market Driven by Rising Incidence
of CKD and Cancer
Ferric Carboxy Maltose Dominates the Global Intravenous Iron
Drugs Market
CKD Leads the Application Segment, Cancer Expected to Witness
Fastest Growth
North America and Europe Hold Major Share, Asia-Pacific
Witnesses Rapid Growth
Low- and Mid-income Countries Present Lucrative Penetration
Opportunities for IV Iron Drugs
The Target Patient Population
Leading Intravenous Iron Drugs Globally
Leading IV Iron Drugs Available in the Market
Leading Intravenous Iron Drugs: In a Nutshell
Ferinject/Injectafer - The Leading Intravenous Iron Drug Globally
EXHIBIT 6: Worldwide Ferinject (Injectafer) Sales (in US$
Million): 2018-2022E
Venofer®
EXHIBIT 7: Worldwide Venofer Sales (in US$ Million): 2018-2022E
Feraheme
EXHIBIT 8: Worldwide Feraheme Sales (in US$ Million): 2018-2022E
Gluconate (Ferrlecit® and Nulecit)
Dextran
Monoferric
Triferic AVNU
INFeD
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Expanding Pool of ESRD and CKD Patients - The Major Growth
Driver for Intravenous (Iv) Iron Drugs
EXHIBIT 9: ESRD Prevalence Worldwide: Number of Treated ESRD
Patients Per Million Population in Select Countries for 2019
EXHIBIT 10: Global Population of Kidney Disease Patients
Undergoing Treatment by Type of Modality (2019 and 2022P):
Percentage Breakdown of Patients Undergoing Dialysis Therapy
and Kidney Transplantation
Dialysis Patients - A Major Market for Intravenous Iron
Supplements
EXHIBIT 11: Global Dialysis Patient Population Breakdown by
Geographic Region/Country (2019 and 2024)
EXHIBIT 12: Global Dialysis Patient Population Distribution by
Modality for Select Countries (2016): Percentage Breakdown of
Hemodialysis (HD) and Peritoneal Dialysis (PD) Patients
Ageing Population Drives Demand for IV Iron Drugs
EXHIBIT 13: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050
EXHIBIT 14: Elderly Population (65+ Years) as a % of Total
Population by Developed, Less Developed and Least Developed
Regions: 2019 & 2030
Rising Incidence of Cancer and the Associated Anemia Drives the
Demand for Intravenous Iron Drugs
EXHIBIT 15: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 16: Breakdown of Total Number of Cancer Cases by
Region: 2020
EXHIBIT 17: Breakdown of Total Number of Cancer Cases by Type:
2020
Rising Incidence of Diabetes to Propel the Market for
Intravenous Iron Drugs
EXHIBIT 18: World Diabetes and Population Statistics (2019,
2030 & 2045)
EXHIBIT 19: Global Prevalence of Diabetes: Number of Adults
Diagnosed with Diabetes (in Million) by Gender for 2019, 2030,
and 2045
Increase in Healthcare Spending Bodes Well for Intravenous Iron
Drugs Market
EXHIBIT 20: Healthcare Expenditure as a % of GDP by Region for
2019
Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
Comparison of Ferrous Salts with IV Iron Therapy
2020: Pharmacosmos Receives FDA Approval for Single Dose
Infusion of Ferric Derisomaltose in IDA Patients
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
New Study Demonstrates IV Iron to Improve Long-term Outcomes in
Heart Failure Patients
EXHIBIT 21: Incidence of Heart Failure (In 000s) in the U.S. by
Gender for the Year 2022
Correction of IDA in Pregnancy Signals Opportunities
Women?s Health - A Key Growth Opportunity
Perioperative and Postoperative Anemia - A Niche Market Beckons
Adverse Reactions of IV Iron Preparations Raise Concerns
Dosing Limitations Plague IV Iron Market
Select Therapeutic Areas and the Required Iron Doses
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Intravenous (IV) Iron Drugs Market Analysis of
Annual Sales in US$ Thousand for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2022 through 2030 and % CAGR
Table 3: World Historic Review for Intravenous (IV) Iron Drugs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 4: World 16-Year Perspective for Intravenous (IV) Iron
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2014,
2023 & 2030
Table 5: World Recent Past, Current & Future Analysis for
Ferric Carboxymaltose by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2022 through 2030 and % CAGR
Table 6: World Historic Review for Ferric Carboxymaltose by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 7: World 16-Year Perspective for Ferric Carboxymaltose by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 8: World Recent Past, Current & Future Analysis for Iron
Dextran by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR
Table 9: World Historic Review for Iron Dextran by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 10: World 16-Year Perspective for Iron Dextran by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 11: World Recent Past, Current & Future Analysis for Iron
Sucrose by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR
Table 12: World Historic Review for Iron Sucrose by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 13: World 16-Year Perspective for Iron Sucrose by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 14: World Recent Past, Current & Future Analysis for
Other Product Types by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR
Table 15: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 16: World 16-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 17: World Recent Past, Current & Future Analysis for
Chronic Kidney Disease by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2022 through 2030 and % CAGR
Table 18: World Historic Review for Chronic Kidney Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 19: World 16-Year Perspective for Chronic Kidney Disease
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 20: World Recent Past, Current & Future Analysis for
Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR
Table 21: World Historic Review for Cancer by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 22: World 16-Year Perspective for Cancer by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 23: World Recent Past, Current & Future Analysis for
Inflammatory Bowel Disease by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2022 through 2030 and % CAGR
Table 24: World Historic Review for Inflammatory Bowel Disease
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 25: World 16-Year Perspective for Inflammatory Bowel
Disease by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 26: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR
Table 27: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 28: World 16-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2023
(E)
Market Analytics
Table 29: USA Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 30: USA Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 31: USA 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 32: USA Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 33: USA Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 34: USA 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
CANADA
Table 35: Canada Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 36: Canada Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 37: Canada 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 38: Canada Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 39: Canada Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 40: Canada 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
JAPAN
Table 41: Japan Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 42: Japan Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 43: Japan 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 44: Japan Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 45: Japan Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 46: Japan 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
CHINA
Table 47: China Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 48: China Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 49: China 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 50: China Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 51: China Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 52: China 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
EUROPE
Intravenous (IV) Iron Drugs Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2023 (E)
Market Analytics
Table 53: Europe Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 54: Europe Historic Review for Intravenous (IV) Iron
Drugs by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2014 through 2021 and %
CAGR
Table 55: Europe 16-Year Perspective for Intravenous (IV) Iron
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2014, 2023 & 2030
Table 56: Europe Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 57: Europe Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 58: Europe 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 59: Europe Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 60: Europe Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 61: Europe 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
FRANCE
Table 62: France Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 63: France Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 64: France 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 65: France Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 66: France Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 67: France 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
GERMANY
Table 68: Germany Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 69: Germany Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 70: Germany 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 71: Germany Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 72: Germany Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 73: Germany 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
ITALY
Table 74: Italy Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 75: Italy Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 76: Italy 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 77: Italy Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 78: Italy Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 79: Italy 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
UNITED KINGDOM
Table 80: UK Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 81: UK Historic Review for Intravenous (IV) Iron Drugs by
Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 82: UK 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 83: UK Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 84: UK Historic Review for Intravenous (IV) Iron Drugs by
Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 85: UK 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
SPAIN
Table 86: Spain Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 87: Spain Historic Review for Intravenous (IV) Iron Drugs
by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron
Sucrose and Other Product Types Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 88: Spain 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 89: Spain Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 90: Spain Historic Review for Intravenous (IV) Iron Drugs
by Application - Chronic Kidney Disease, Cancer, Inflammatory
Bowel Disease and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 91: Spain 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
RUSSIA
Table 92: Russia Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 93: Russia Historic Review for Intravenous (IV) Iron
Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran,
Iron Sucrose and Other Product Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 94: Russia 16-Year Perspective for Intravenous (IV) Iron
Drugs by Product Type - Percentage Breakdown of Value Sales for
Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other
Product Types for the Years 2014, 2023 & 2030
Table 95: Russia Recent Past, Current & Future Analysis for
Intravenous (IV) Iron Drugs by Application - Chronic Kidney
Disease, Cancer, Inflammatory Bowel Disease and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 96: Russia Historic Review for Intravenous (IV) Iron
Drugs by Application - Chronic Kidney Disease, Cancer,
Inflammatory Bowel Disease and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 97: Russia 16-Year Perspective for Intravenous (IV) Iron
Drugs by Application - Percentage Breakdown of Value Sales for
Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and
Other Applications for the Years 2014, 2023 & 2030
REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Intravenous (IV) Iron Drugs by Product Type - Ferric
Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 99: Rest of Europe Historic Review for Intravenous (IV)
Iron Drugs by Product Type - Ferric Carboxymaltose, Iron
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06051284/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________